Physician profile
Roya Zandi
NPI 1083131296
$1,683.86
in general payments reported to CMS, 2019-2025
8 companies · $258 in 2025
The $258 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $235 · 2023: $619 · 2024: $572 · 2025: $258.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,449.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,448.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec USA, INC. | $485.88 | 2023-2024 | Iolmaster 700, Veracity Surgical, Artevo 800 |
| New World Medical,INC. | $344.36 | 2024 | Kahook Dual Blade, Ahmed Glaucoma Valve, Streamline |
| Glaukos Corporation | $265.79 | 2024-2025 | Istent Infinite, Idosetr, Istent Trabecular Micro-Bypass System Model Is3 |
| Horizon Therapeutics Plc | $228.72 | 2021-2023 | Tepezza |
| Alcon Vision LLC | $171.48 | 2023-2024 | Rhopressa, Simbrinza, Rocklatan |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $123.22 | 2021 | |
| Sight Sciences, INC. | $34.20 | 2025 | Omni Surgical System |
| Apellis Pharmaceuticals, INC. | $30.21 | 2023 | Syfovre |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roya Zandi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.